Marinus Pharmaceuticals Company Profile (NASDAQ:MRNS)

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MRNS
  • CUSIP: N/A
  • Web: www.marinuspharma.com
Capitalization:
  • Market Cap: $26.23 million
  • Outstanding Shares: 22,419,000
Average Prices:
  • 50 Day Moving Avg: $1.37
  • 200 Day Moving Avg: $1.27
  • 52 Week Range: $0.82 - $6.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.23
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.88 per share
  • Price / Book: 1.33
Profitability:
  • EBIDTA: ($26,500,000.00)
  • Return on Equity: -79.45%
  • Return on Assets: -60.04%
Debt:
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 4.04%
  • Quick Ratio: 4.04%
Misc:
  • Average Volume: 480,484 shs.
  • Beta: 2.08
  • Short Ratio: 2.72
 

Frequently Asked Questions for Marinus Pharmaceuticals (NASDAQ:MRNS)

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) released its quarterly earnings data on Monday, May, 1st. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. View Marinus Pharmaceuticals' Earnings History.

Where is Marinus Pharmaceuticals' stock going? Where will Marinus Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued twelve-month target prices for Marinus Pharmaceuticals' shares. Their predictions range from $2.00 to $3.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $2.50 in the next year. View Analyst Ratings for Marinus Pharmaceuticals.

What are analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (3/17/2017)
  • 2. Oppenheimer Holdings Inc. analysts commented, "As we only took into account the adult epilepsy indication in our valuation, and left any contribution from the other programs as upside, we are moving to a Perform rating," (6/14/2016)

Who are some of Marinus Pharmaceuticals' key competitors?

Who owns Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (6.18%), Nexthera Capital LP (3.57%), Granite Point Capital Management L.P. (3.60%), Vanguard Group Inc. (3.03%), Jennison Associates LLC (1.81%) and KCG Holdings Inc. (0.30%). Company insiders that own Marinus Pharmaceuticals stock include Anand Mehra and Vii Lp Canaan. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Who sold Marinus Pharmaceuticals stock? Who is selling Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD.. Company insiders that have sold Marinus Pharmaceuticals stock in the last year include Anand Mehra and Vii Lp Canaan. View Insider Buying and Selling for Marinus Pharmaceuticals.

Who bought Marinus Pharmaceuticals stock? Who is buying Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Granite Point Capital Management L.P., Vanguard Group Inc., Jennison Associates LLC and KCG Holdings Inc.. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy Marinus Pharmaceuticals stock?

Shares of Marinus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Marinus Pharmaceuticals stock cost?

One share of Marinus Pharmaceuticals stock can currently be purchased for approximately $1.17.

Analyst Ratings

Consensus Ratings for Marinus Pharmaceuticals (NASDAQ:MRNS) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $2.50 (113.68% upside)

Analysts' Ratings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2016Jefferies Group LLCReiterated RatingBuy$3.00N/AView Rating Details
6/28/2016Stifel NicolausReiterated RatingHoldN/AView Rating Details
6/14/2016Goldman Sachs Group IncDowngradeBuy -> NeutralN/AView Rating Details
6/14/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$14.00 -> $2.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Earnings by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Earnings History by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.32)($0.26)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.33)($0.31)ViewN/AView Earnings Details
11/3/2016Q3($0.43)($0.33)ViewN/AView Earnings Details
8/9/2016Q2($0.38)($0.46)ViewN/AView Earnings Details
5/2/2016Q1 2016($0.41)($0.37)ViewN/AView Earnings Details
3/7/2016Q416($0.38)($0.45)ViewN/AView Earnings Details
10/29/2015Q3 2015($0.51)($0.35)ViewN/AView Earnings Details
8/4/2015Q2 2015($0.51)($0.37)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.47)($0.50)ViewN/AView Earnings Details
11/13/2014Q3 14($0.50)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)
2017 EPS Consensus Estimate: ($0.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Marinus Pharmaceuticals (NASDAQ:MRNS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 30.88%
Insider Trades by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Insider Trades by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Anand MehraMajor ShareholderSell750,683$1.39$1,043,449.37View SEC Filing  
8/8/2016Vii Lp CanaanMajor ShareholderSell149,154$1.50$223,731.00View SEC Filing  
8/4/2016Vii Lp CanaanMajor ShareholderSell145,583$1.50$218,374.50View SEC Filing  
7/29/2016Vii Lp CanaanMajor ShareholderSell24,540$1.71$41,963.40View SEC Filing  
7/27/2016Vii Lp CanaanMajor ShareholderSell20,589$1.81$37,266.09View SEC Filing  
7/26/2016Vii Lp CanaanMajor ShareholderSell20,380$1.81$36,887.80View SEC Filing  
7/25/2016Vii Lp CanaanMajor ShareholderSell270,750$1.90$514,425.00View SEC Filing  
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Marinus Pharmaceuticals (NASDAQ:MRNS)
Latest Headlines for Marinus Pharmaceuticals (NASDAQ:MRNS)
Source:
DateHeadline
prnewswire.com logoHow These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma - PR Newswire (press release)
www.prnewswire.com - May 18 at 8:24 AM
americanbankingnews.com logoMarinus Pharmaceuticals (MRNS) Receiving Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 6:46 PM
americanbankingnews.com logoMarinus Pharmaceuticals Inc (MRNS) Releases Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - May 2 at 11:20 AM
americanbankingnews.com logoMarinus Pharmaceuticals Inc (MRNS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 2 at 8:04 AM
finance.yahoo.com logoMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 1 at 12:31 PM
finance.yahoo.com logoMarinus Pharmaceuticals posts 1Q loss
finance.yahoo.com - May 1 at 12:31 PM
americanbankingnews.com logoMarinus Pharmaceuticals (MRNS) Earns Daily Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 30 at 9:38 AM
americanbankingnews.com logoMarinus Pharmaceuticals (MRNS) Getting Positive News Coverage, Study Shows
www.americanbankingnews.com - April 27 at 2:24 PM
americanbankingnews.com logo-$0.27 EPS Expected for Marinus Pharmaceuticals Inc (MRNS) This Quarter
www.americanbankingnews.com - April 27 at 1:11 AM
streetinsider.com logoMarinus Pharma (MRNS) to Present Ganaxolone DATA at AAN - StreetInsider.com
www.streetinsider.com - April 20 at 9:55 AM
streetinsider.com logoMarinus Pharma (MRNS) to Present Ganaxolone DATA at AAN
www.streetinsider.com - April 18 at 10:19 AM
finance.yahoo.com logoMarinus to present Ganaxolone DATA at American academy of neurology annual meeting
finance.yahoo.com - April 18 at 10:19 AM
americanbankingnews.com logoMarinus Pharmaceuticals (MRNS) Earns Daily Media Impact Score of 0.39
www.americanbankingnews.com - April 13 at 3:18 PM
streetinsider.com logoMarinus Pharma (MRNS) Announces Lorianne Masuoka as New Chief Medical Officer - StreetInsider.com
www.streetinsider.com - April 13 at 8:32 AM
finance.yahoo.com logoDr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
finance.yahoo.com - April 11 at 11:09 AM
finance.yahoo.com logoGanaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
finance.yahoo.com - April 10 at 10:23 AM
americanbankingnews.com logoMarinus Pharmaceuticals Inc (MRNS) Expected to Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 7 at 5:44 PM
americanbankingnews.com logoZacks: Brokerages Expect Marinus Pharmaceuticals Inc (MRNS) Will Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - April 5 at 4:07 PM
americanbankingnews.com logoMarinus Pharmaceuticals Inc (MRNS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 10:04 AM
investopedia.com logoUltragenyxs’ Seizure Drug Fails Study
www.investopedia.com - March 23 at 7:09 PM
biz.yahoo.com logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - March 22 at 6:44 PM
finance.yahoo.com logoMARINUS PHARMACEUTICALS INC Financials
finance.yahoo.com - March 16 at 7:22 PM
finance.yahoo.com logoMarinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
finance.yahoo.com - March 15 at 6:51 PM
americanbankingnews.com logoMarinus Pharmaceuticals Inc (MRNS) Expected to Post Q1 2017 Earnings of ($0.27) Per Share
www.americanbankingnews.com - March 15 at 10:11 AM
finance.yahoo.com logoMarinus Pharmaceuticals Provides Business Update and 2016 Financial Results
finance.yahoo.com - March 13 at 10:16 AM
biz.yahoo.com logoMARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 10:16 AM
bizjournals.com logoTechnical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma
www.bizjournals.com - February 28 at 10:13 AM
streetinsider.com logoMarinus Pharma (MRNS) Says Study Shows Ganaxolone Reduces ... - StreetInsider.com
www.streetinsider.com - February 14 at 8:15 PM
finance.yahoo.com logoGanaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
finance.yahoo.com - February 14 at 8:15 PM
finance.yahoo.com logo7:31 am Marinus Pharmaceuticals announces the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAa, ganaxolone ameliorates many of the behavioral abnormalities in
finance.yahoo.com - February 14 at 8:15 PM
biz.yahoo.com logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - February 8 at 7:32 PM
globenewswire.com logoMarinus Appoints Michael R. Dougherty to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 1 at 7:43 PM
finance.yahoo.com logoMarinus Appoints Michael R. Dougherty to its Board of Directors
finance.yahoo.com - February 1 at 7:43 PM
streetinsider.com logoForm 8-K MARINUS PHARMACEUTICALS For: Jan 23
www.streetinsider.com - January 24 at 7:23 PM
nasdaq.com logoMid-Day Market Update: Marinus Pharma Surges Following ... - Nasdaq
www.nasdaq.com - January 24 at 5:01 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Halliburton, Marinus Pharma - Nasdaq
www.nasdaq.com - January 24 at 5:01 AM
streetinsider.com logoMarinus Pharma (MRNS) Announes Positive Preliminary Data from CDKL5 Patients Enrolled in Ongoing Phase 2 ... - StreetInsider.com
www.streetinsider.com - January 24 at 5:01 AM
investopedia.com logoMarinus Spikes on Positive Seizure Drug Data (MRNS)
www.investopedia.com - January 23 at 6:58 PM
marketwatch.com logoMarinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug
www.marketwatch.com - January 23 at 6:58 PM
investopedia.com logoMarinus Anti-Seizure Drug Did Well in Early Trial
www.investopedia.com - January 23 at 6:58 PM
finance.yahoo.com logoWhy This Seizure Drug Matters So Much for Marinus Pharma
finance.yahoo.com - January 23 at 6:57 PM
us.rd.yahoo.com logoMarinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
us.rd.yahoo.com - January 23 at 10:06 AM
biz.yahoo.com logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 19 at 9:20 PM

Social

Chart

Marinus Pharmaceuticals (MRNS) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff